Table 2 Chemotherapy dosings (n = 66) as a total number and as a percentage
From: Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma
Capecitabine dose administered | Number of patients (percent) |
|---|---|
Number of patients starting at full dose (750–825 mg/m 2 ) | |
- No subsequent dose reduction | 59 (78%) |
- Dose reduction | 13 (22%) |
- Discontinuation | 0 (0%) |
Number of patients starting at dose level −1 (500–749 mg/m 2 ) | |
- Received | 7 (11%) |
- Dose reduction | 0 (0%) |
- Discontinuation | 0 (0%) |
Mean weeks of capectiabine | 5.5 (2.5-6) |
Mitomycin dose administered | Number of patients (percent) |
- Full dose (12 mg/m 2 ) | 63 (95%) |
- Dose level −1 | 3 (5%) |